AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8450099
Drug: Immediate cognitive-behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate cognitive-behavior therapy (8-week group intervention)
Trial: 8450099
Drug: Delayed cognitive-behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed cognitive-behavior therapy (8-week group intervention)
Trial: 31672172
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (G, n=7)
Trial: 21361732
Drug: O2A1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O2A1 group (omeprazole 20 mg twice/day plus amoxicillin 250 mg 4 times/day)
Trial: 21361732
Drug: O1A1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O1A1 group (omeprazole 20 mg once/day plus amoxicillin 250 mg 4 times/day)
Trial: 21361732
Drug: Subsequent antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent antibiotic susceptibility‐driven proton pump inhibitor‐based triple therapy
Trial: 12660485
Drug: Deep sclerectomy
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sclerectomy with implant (DS)
Trial: 10981569
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg every 8 h
Trial: 23777506
Drug: Miglitol 50
RxNorm normalized name: miglitol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 50 mg with each meal for 1 week
Trial: 23777506
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anti-diabetic agent for 1 week)
Trial: 20620320
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (ceftriaxone and metronidazole, once daily for a minimum of 5 days)
Trial: 20620320
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (amoxicillin/clavulanate, after tolerating a regular diet for 7 days)
Trial: 16644316
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin (81 mg)
Trial: 16644316
Drug: Standard aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard aspirin (81 mg)
Trial: 10780937
Drug: Enteral Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral Glutamine (0.5 g x kg(‐1) x day(‐1) for 2 days)
Trial: 1652611
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus prochlorperazine 10 mg every 6 hr
Trial: 31818266
Drug: Routine dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine dialysis initiation at eGFR 7 ml/min/1.73 m2
Trial: 31818266
Drug: Deferred dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred dialysis initiation at eGFR 5 ml/min/1.73 m2 or less
Trial: 26545541
Drug: Stretching program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching program performed twice a week for eight weeks
Trial: 21526923
Drug: Bevacizumab administered
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab administered monthly
Trial: 21526923
Drug: Bevacizumab administered
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab administered as needed
Trial: 21526923
Drug: Ranibizumab administered
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab administered as needed
Trial: 19525191
Drug: Short-course rituximab/chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course rituximab/chemotherapy
Trial: 15673996
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of standardized turmeric extract taken daily for 8 weeks
Trial: 11350464
Drug: Saline 1
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 1 mL
Trial: 7008244
Drug: PT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT group (anticoagulant dosage according to PT)
Trial: 9617377
Drug: 5-HT3 receptor
RxNorm normalized name: 5-HT3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonist plus dexamethasone
Trial: 26669548
Drug: Roughened surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roughened surface implants
Trial: 22739141
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH; 150 U/kg)
Trial: 22739141
Drug: All heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All heparin treatments
Trial: 8847874
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate (200 mg/day)
Trial: 14644895
Drug: Menopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal hormone therapy (HT)
Trial: 8510086
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25-100 mg four times daily
Trial: 27787895
Drug: Ultrasound-guided, single-injection,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided, single-injection, femoral nerve block followed by continuous fascia iliaca block
Trial: 18416885
Drug: Collagen hydrolysate
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen hydrolysate (CH) 10 g in 25 mL liquid formulation
Trial: 18416885
Drug: Placebo (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (25 mL liquid containing xanthan)
Trial: 15665549
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg three times a day for 2 months
Trial: 11839142
Drug: NRTI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI + protease inhibitor
Trial: 10084409
Drug: Piperacillin/tazobactam (P/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (P/T) 4.5 g i.v. every six hours (n = 75)
Trial: 10084409
Drug: Imipenem/cilastatin (I/C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (I/C) 500 mg i.v. every six hours (n = 75)
Trial: 7781402
Drug: Concurrent and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent and alternating chemotherapy strategies
Trial: 6650444
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment of 400 mg cholesterol per day with exercise (MX)
Trial: 6650444
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment of 1400 mg cholesterol per day with exercise (HX)
Trial: 6650444
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment of 1400 mg cholesterol per day without exercise (HS)
Trial: 28787388
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus (2 daily oral doses of 2 × 10 CFUs for 5 days)
Trial: 28787388
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 daily doses for 5 days)
Trial: 24214140
Drug: Topical brimonidine
RxNorm normalized name: brimonidine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical brimonidine (0.2 %) twice daily for 6 months
Trial: 11772828
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block with 10 mL of 0.5% bupivacaine
Trial: 11772828
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block with 10 mL of 0.9% saline (placebo)
Trial: 7807622
Drug: Case management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case management using trained community health workers with thrice weekly home visits and treatment based on WHO recommendations
Trial: 2561409
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 x 4 mg daily by inhalation)
Trial: 31813384
Drug: High-oleic peanuts
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-oleic peanuts (56 g) within a hypoenergetic diet
Trial: 31813384
Drug: Conventional peanuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional peanuts (56 g) within a hypoenergetic diet
Trial: 18068281
Drug: Hypomethylating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypomethylating agents (azacytidine and decitabine)
Trial: 17302078
Drug: Sevoflurane administered
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane administered with tidal volume breathing (n=15)
Trial: 17302078
Drug: Sevoflurane administered
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane administered with vital capacity breaths (n=15)
Trial: 9366624
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of Hormone Use interview (HHU) at the 3-month follow-up visit (HHU3mos)
Trial: 9366624
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of Hormone Use interview (HHU) at the 3-year follow-up (HHU3yrs)
Trial: 8322143
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate
Trial: 30652487
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (no amendments)
Trial: 22669332
Drug: Ral 60
RxNorm normalized name: SYRINGE,ORAL 60ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ral 60 mg
Trial: 22669332
Drug: Ral 30
RxNorm normalized name: Aloral 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ral 30 mg
Trial: 22669332
Drug: n-3FA (Lovaza)
RxNorm normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3FA (Lovaza) 4 g
Trial: 22669332
Drug: Lovaza 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaza 4 g + Ral 30 mg
Trial: 20055694
Drug: Two-compound product
RxNorm normalized name: Ceo-Two Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound product (calcipotriol/betamethasone dipropionate)
Trial: 20055694
Drug: Calcipotriol (Cp)
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol (Cp) monotherapy
Trial: 20055694
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate (BD) monotherapy
Trial: 18678843
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (tolterodine + behavioral training)
Trial: 18678843
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy alone (tolterodine)
Trial: 12855088
Drug: NTC (No
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTC (No Treatment Condition, just an interview)
Trial: 10476617
Drug: Ozagrel Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Ozagrel (DB12017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozagrel Hydrochloride (400 mg/day, orally)
Trial: 8724617
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms of oral misoprostol every 3 hours up to 5 doses
Trial: 1680266
Drug: Ketobemidone (Ketogan)
RxNorm normalized name: chlorhexidine
DrugBank: Ketobemidone (DB06738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketobemidone (Ketogan) 1-1.5 ml
Trial: 24043299
Drug: On-treatment CRP
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment CRP levels
Trial: 15140341
Drug: Telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin 800 mg once daily for 7 days
Trial: 1959402
Drug: Albuterol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (5 mg)
Trial: 3296867
Drug: Metaproterenol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (15 mg)
Trial: 31402563
Drug: Lateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral injection points performed first
Trial: 31402563
Drug: Medial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial injection points performed first
Trial: 17070267
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) solution
Trial: 15342616
Drug: 8 patches
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 patches
Trial: 15342616
Drug: 2 patches
RxNorm normalized name: Qutenza 8% Topical Patch Kit (2 Patches)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 patches
Trial: 15342616
Drug: 4 and
RxNorm normalized name: Adenovirus types 4 and 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 and 8 patches
Trial: 1768820
Drug: Midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.15 mg/kg)
Trial: 9540175
Drug: RCT +
RxNorm normalized name: Recombinant tissue plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT + A (amifostine 500 mg prior to carboplatin)
Trial: 6351333
Drug: Atropine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.6 mg)
Trial: 346541
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no medications)
Trial: 9186381
Drug: Aspirin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (160 mg/day)
Trial: 3549601
Drug: Ticlopidine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (500 mg/day)
Trial: 8280822
Drug: Ranitidine continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine continuous i.v. infusion (6.25 mg/h)
Trial: 26808865
Drug: Raw milk
RxNorm normalized name: raw sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw milk with no drug residues (NR)
Trial: 24089302
Drug: Intraarticular hyaluronan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronan injection (HS)
Trial: 20522296
Drug: Locally produced
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally produced soy/peanut ready-to-use supplementary food (RUSF) at a dosage of 65 kcal/kg/d for up to 8 weeks.
Trial: 18622133
Drug: Singing bowl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Singing bowl therapy (IG)
Trial: 18622133
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (KG)
Trial: 15768874
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Chinese herbs
Trial: 9190003
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 40 mg of prednisone
Trial: 24470281
Drug: EPA-FFA 2
RxNorm normalized name: EPA
DrugBank: Icosapent (DB00159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-FFA 2 g daily
Trial: 16651509
Drug: Sertraline (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (n = 79)
Trial: 14717039
Drug: Brief information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief information and relaxation therapy
Trial: 25010430
Drug: Integrated cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive-behavioral therapy (CBT) and voucher-based reinforcement therapy (VBRT)
Trial: 25010430
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with attendance-based reward program
Trial: 20863381
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in dose of other oral agents (n = 39)
Trial: 15965356
Drug: Nicorandil (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (15 mg/d)
Trial: 1906905
Drug: 0.4 or
RxNorm normalized name: 0.4 Orencia 125 MG/ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 or 0.8 mg of nitroglycerin
Trial: 1906905
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg of cocaine
Trial: 6652641
Drug: Symptom duration
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom duration prior to treatment in patients with faster-growing tumors
Trial: 6652641
Drug: Breast cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer control activities to decrease the interval from recognition of symptoms to diagnosis and treatment
Trial: 6652641
Drug: Early diagnosis
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early diagnosis and treatment during the symptomatic period for patients with faster-growing tumors
Trial: 31278224
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vitamin K (n=41)
Trial: 29574355
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg/d) plus trifluoperazine (5 mg/d)
Trial: 29574355
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg/d) alone
Trial: 24634003
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day, 4 weeks on/2 weeks off)
Trial: 20585005
Drug: Glutamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.25 g/kg/dose)
Trial: 3903785
Drug: Triletide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triletide (1.5 g/day)
Trial: 3903785
Drug: Carbenoxolone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (0.3 g/day)
Trial: 27856714
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 15 l/min
Trial: 31254849
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 30 l/min
Trial: 27856714
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 45 l/min
Trial: 23460810
Drug: Xiaoke Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoke Pill
Trial: 11990832
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) therapy
Trial: 2527531
Drug: Cilazapril (oral)
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (oral)
Trial: 2527531
Drug: Cilazaprilat (oral)
RxNorm normalized name: cilazapril
DrugBank: Cilazaprilat (DB15565)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazaprilat (oral)
Trial: 30672254
Drug: Fan-needle radiofrequency
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fan-needle radiofrequency guided by meridians-muscles theory, treated at tendon nodes around knee joints (ashi points), 4 points per treatment, once every two weeks for 2 treatments.
Trial: 30672254
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of celecoxib capsules, 1 capsule every day for 4 weeks.
Trial: 14597936
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg/d
Trial: 17035949
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg/day for 1 year)
Trial: 17035949
Drug: Angiotensin‐converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐converting enzyme inhibitors and/or angiotensin type 1 receptor antagonists alone
Trial: 24661576
Drug: Xylo-oligosaccharides (XOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylo-oligosaccharides (XOS) 8 g/d
Trial: 12370798
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin 200 IU daily for 3 months